Neoadjuvant Therapy in Rectal Cancer

被引:107
作者
Fleming, Fergal J. [1 ]
Pahlman, Lars [2 ]
Monson, John R. T. [1 ]
机构
[1] Univ Rochester, Med Ctr, Div Colorectal Surg, Rochester, NY 14642 USA
[2] Univ Uppsala Hosp, Dept Surg Sci, Uppsala, Sweden
关键词
Radiotherapy; Chemotherapy; Rectal cancer; CIRCUMFERENTIAL RESECTION MARGIN; COURSE PREOPERATIVE RADIOTHERAPY; TOTAL MESORECTAL EXCISION; LOCAL RECURRENCE; POSTOPERATIVE CHEMORADIOTHERAPY; IRRADIATED PATIENTS; PROGNOSTIC-FACTORS; RISK-FACTORS; PHASE-III; MRC CR07;
D O I
10.1007/DCR.0b013e31820eeb37
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
BACKGROUND: The optimal type of neoadjuvant therapy regimen in rectal cancer is contentious. OBJECTIVE: This study aimed to review the impact of neoadjuvant therapy on oncological outcomes and complications (short and long term) in patients undergoing total mesorectal excision for rectal cancer. DATA SOURCES: An electronic search of MEDLINE, PubMed, EMBASE, and the Cochrane Database of Collected Reviews was performed through March 2010. STUDY SELECTION: Key-word combinations including rectal cancer, total mesorectal excision, radiotherapy, chemotherapy, endorectal ultrasound, and magnetic resonance imaging were used to identify randomized control trials where chemotherapy and/or radiotherapy were deployed before resectional surgery. INTERVENTION(S): Patients underwent total mesorectal excision for rectal cancer who did and did not receive preoperative chemotherapy and/or radiotherapy. MAIN OUTCOME MEASURES: The main outcome measures comprised the impact of the addition of neoadjuvant therapy to total mesorectal excision on the perioperative complication rate, the pathological complete response rate, the rate of local recurrence, and long- term treatment-related complications. RESULTS: A total of 12 randomized control trials involving 9410 patients were included. Both short-course radiotherapy and long-course chemoradiation can offer a relative risk reduction of 50% in local recurrence in appropriately selected patients with stage II and III rectal cancer. This oncological benefit comes at the cost of a relative risk increase of 50% in both acute treatment-related toxicity and long-term anorectal dysfunction. LIMITATIONS: Preoperative staging provides only an estimate of the "true" tumor stage that can only be determined by histological assessment of the tumor specimen which renders appropriate patient selection challenging. CONCLUSIONS: The current treatment trade-off of a relative risk reduction of local recurrence of 50% at the cost of a relative increase of 50% in treatment-related complications underpins the need for more accurate patient staging and more precise delivery of neoadjuvant therapy.
引用
收藏
页码:901 / 912
页数:12
相关论文
共 58 条
[1]
ROLE OF CIRCUMFERENTIAL MARGIN INVOLVEMENT IN THE LOCAL RECURRENCE OF RECTAL-CANCER [J].
ADAM, IJ ;
MOHAMDEE, MO ;
MARTIN, IG ;
SCOTT, N ;
FINAN, PJ ;
JOHNSTON, D ;
DIXON, MF ;
QUIRKE, P .
LANCET, 1994, 344 (8924) :707-711
[2]
[Anonymous], 1993, Br J Surg, V80, P1333
[3]
[Anonymous], Colorectal cancer facts & figures . 2020‐2022.
[4]
[Anonymous], NCCN CLIN PRACT GUID
[5]
Aschele C, 2009, J CLIN ONCOL, V27
[6]
Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1 [J].
Berardi, Rossana ;
Maccaroni, Elena ;
Onofri, Azzurra ;
Giampieri, Riccardo ;
Bittoni, Alessandro ;
Pistelli, Mirco ;
Scartozzi, Mario ;
Pierantoni, Chiara ;
Bianconi, Maristella ;
Cascinu, Stefano .
EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (14) :2245-2258
[7]
Circumferential resection margin as a prognostic factor in rectal cancer [J].
Bernstein, T. E. ;
Endreseth, B. H. ;
Romundstad, P. ;
Wibe, A. .
BRITISH JOURNAL OF SURGERY, 2009, 96 (11) :1348-1357
[8]
Rectal cancer: Local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging - A meta-analysis [J].
Bipat, S ;
Glas, AS ;
Slors, FJM ;
Zwinderman, AH ;
Bossuyt, PMM ;
Stoker, J .
RADIOLOGY, 2004, 232 (03) :773-783
[9]
Birgisson H, 2008, BRIT J SURG, V95, P206, DOI 10.1002/bjs.5918
[10]
Occurrence of second cancers in patients treated with radiotherapy for rectal cancer [J].
Birgisson, H ;
Påhlman, L ;
Gunnarsson, U ;
Glimelius, B .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :6126-6131